Olgu Sunumu

Rifampicin Hypersensitivity in a Pediatric Case of Brucellosis: A Case Report

Cilt: 10 Sayı: 2 20 Ağustos 2026
PDF İndir
TR EN

Rifampicin Hypersensitivity in a Pediatric Case of Brucellosis: A Case Report

Öz

Background: Brucellosis is a zoonotic infection that remains endemic in many regions and represents a significant public health problem. Clinical manifestations in children are often nonspecific, and musculoskeletal involvement is among the most frequent focal complications. Combination therapy with rifampicin and doxycycline, or rifampicin and trimethoprim–sulfamethoxazole in pediatric patients, is recommended as first-line treatment. However, drug hypersensitivity may complicate management and limit therapeutic options. Case Presentation: We report the case of a previously healthy 10-year-old boy who presented with fever and left knee pain following close contact with sheep. Brucellosis was confirmed by positive standard agglutination and Coombs tests. He was initially treated with doxycycline and rifampicin. After two weeks, the patient developed fever, vomiting, pruritus, conjunctivitis, eosinophilia, and elevated transaminases. Symptoms resolved upon discontinuation of rifampicin and recurred after re-initiation of anti-brucellosis therapy, strongly suggesting rifampicin hypersensitivity. Pediatric allergy consultation confirmed the suspicion, and rifampicin was permanently withdrawn. The patient was successfully treated with doxycycline and gentamicin (14 days of gentamicin, doxycycline for 6 weeks), leading to full clinical and laboratory recovery. Conclusion: Rifampicin and doxycycline are essential first-line agents in the treatment of pediatric brucellosis in children older than 8 years, but hypersensitivity reactions, though rare, may mimic disease relapse or complications. To our knowledge, this is the first reported pediatric case of rifampicin hypersensitivity in brucellosis. Awareness of this possibility is crucial for timely recognition and appropriate management. Alternative regimens, such as doxycycline combined with aminoglycosides, can provide effective treatment in children unable to tolerate rifampicin.

Anahtar Kelimeler

Kaynakça

  1. Abramson, O., Abu-Rashid, M., Gorodischer, R., et al. (1997). Failure of short antimicrobial treatments for human brucellosis. Antimicrobial Agents and Chemotherapy, 41(7), 1621–1622. https://doi.org/10.1128/AAC.41.7.1621 PMID: 9210701; PMCID: PMC163975.
  2. Çiftdoğan, D. Y., & Aslan, S. (2020). Osteoarticular involvement of brucellosis in pediatric patients: clinical and laboratory characteristics. The Turkish Journal of Pediatrics, 62(2), 199–207. doi: 10.24953/turkjped.2020.02.005. PMID: 32419411.
  3. Editorial Board of Chinese Journal of Infectious Diseases. (2017). Expert consensus on the diagnosis and treatment of brucellosis. Chinese Journal of Infectious Diseases, 35(12), 705–710. [in Chinese].
  4. Franco, M. P., Mulder, M., Gilman, R. H., et al. (2007). Human brucellosis. The Lancet Infectious Diseases, 7(12), 775–786. https://doi.org/10.1016/S1473-3099(07)70286-4 PMID: 18045560.
  5. Justman, N., Fruchtman, Y., Greenberg, D., et al. (2018). Hematologic manifestations of brucellosis in children. The Pediatric Infectious Disease Journal, 37(6), 586–591. https://doi.org/10.1097/INF.0000000000001900 PMID: 29329166.
  6. Maletskaia, O. V. (2002). Effektivnost' nekotorykh novykh antibiotikov pri lechenii eksperimental'nogo brutselleza. Antibiotiki I Khimioterapiia, 47(11), 13–17 Russian. PMID: 12698575.
  7. Qasim, S. S., Alshuwaier, K., Alosaimi, M. Q., et al. (2020). Brucellosis in Saudi children: presentation, complications, and treatment outcome. Cureus, 12(11), e11289. https://doi.org/10.7759/cureus.11289
  8. Tanir, G., Tufekci, S. B., & Tuygun, N. (2009). Presentation, complications, and treatment outcome of brucellosis in Turkish children. Pediatrics International, 51(1), 114–119. doi: 10.1111/j.1442-200X.2008.02661.x. PMID: 19371290.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Bulaşıcı Hastalıklar

Bölüm

Olgu Sunumu

Yayımlanma Tarihi

20 Ağustos 2026

Gönderilme Tarihi

13 Ocak 2026

Kabul Tarihi

22 Haziran 2026

Yayımlandığı Sayı

Yıl 2026 Cilt: 10 Sayı: 2

Kaynak Göster

APA
Yildirim Arslan, S., & Kendirci, N. (2026). Rifampicin Hypersensitivity in a Pediatric Case of Brucellosis: A Case Report. Balıkesir Medical Journal, 10(2), 91-96. https://doi.org/10.33716/bmedj.1862973
AMA
1.Yildirim Arslan S, Kendirci N. Rifampicin Hypersensitivity in a Pediatric Case of Brucellosis: A Case Report. BMedJ. 2026;10(2):91-96. doi:10.33716/bmedj.1862973
Chicago
Yildirim Arslan, Sema, ve Nergiz Kendirci. 2026. “Rifampicin Hypersensitivity in a Pediatric Case of Brucellosis: A Case Report”. Balıkesir Medical Journal 10 (2): 91-96. https://doi.org/10.33716/bmedj.1862973.
EndNote
Yildirim Arslan S, Kendirci N (01 Ağustos 2026) Rifampicin Hypersensitivity in a Pediatric Case of Brucellosis: A Case Report. Balıkesir Medical Journal 10 2 91–96.
IEEE
[1]S. Yildirim Arslan ve N. Kendirci, “Rifampicin Hypersensitivity in a Pediatric Case of Brucellosis: A Case Report”, BMedJ, c. 10, sy 2, ss. 91–96, Ağu. 2026, doi: 10.33716/bmedj.1862973.
ISNAD
Yildirim Arslan, Sema - Kendirci, Nergiz. “Rifampicin Hypersensitivity in a Pediatric Case of Brucellosis: A Case Report”. Balıkesir Medical Journal 10/2 (01 Ağustos 2026): 91-96. https://doi.org/10.33716/bmedj.1862973.
JAMA
1.Yildirim Arslan S, Kendirci N. Rifampicin Hypersensitivity in a Pediatric Case of Brucellosis: A Case Report. BMedJ. 2026;10:91–96.
MLA
Yildirim Arslan, Sema, ve Nergiz Kendirci. “Rifampicin Hypersensitivity in a Pediatric Case of Brucellosis: A Case Report”. Balıkesir Medical Journal, c. 10, sy 2, Ağustos 2026, ss. 91-96, doi:10.33716/bmedj.1862973.
Vancouver
1.Sema Yildirim Arslan, Nergiz Kendirci. Rifampicin Hypersensitivity in a Pediatric Case of Brucellosis: A Case Report. BMedJ. 01 Ağustos 2026;10(2):91-6. doi:10.33716/bmedj.1862973